Production (Stage)
Ligand Pharmaceuticals Incorporated
LGND
$105.99
$1.811.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.40% | 27.28% | -0.76% | -25.82% | -41.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.40% | 27.28% | -0.76% | -25.82% | -41.92% |
| Cost of Revenue | 134.41% | -7.28% | -44.89% | -54.51% | -60.75% |
| Gross Profit | 21.37% | 39.86% | 26.56% | -6.20% | -28.32% |
| SG&A Expenses | 63.57% | 48.99% | 1.64% | -13.16% | -23.34% |
| Depreciation & Amortization | -0.81% | -2.07% | -2.41% | -3.41% | -2.62% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.50% | 18.62% | -16.24% | -28.48% | -36.53% |
| Operating Income | -1,090.97% | 134.41% | 359.77% | 78.72% | -109.24% |
| Income Before Tax | -232.52% | -96.04% | -16.81% | -44.32% | 20.74% |
| Income Tax Expenses | -212.92% | -33.44% | -72.64% | -79.95% | -48.90% |
| Earnings from Continuing Operations | -237.65% | -107.49% | 114.46% | 2.75% | 87.72% |
| Earnings from Discontinued Operations | -- | -- | 100.00% | 100.00% | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -237.65% | -107.73% | 174.52% | 55.18% | 301.89% |
| EBIT | -1,090.97% | 134.41% | 359.77% | 78.72% | -109.24% |
| EBITDA | -47.78% | 25.72% | 68.15% | -7.08% | -43.88% |
| EPS Basic | -230.86% | -101.63% | 172.62% | 53.72% | 290.26% |
| Normalized Basic EPS | -2,059.11% | -197.88% | -335.06% | -339.47% | -86.61% |
| EPS Diluted | -233.88% | -105.55% | 198.62% | 59.04% | 318.38% |
| Normalized Diluted EPS | -2,100.32% | -203.43% | -286.92% | -372.60% | -86.10% |
| Average Basic Shares Outstanding | 6.81% | 5.74% | 4.43% | 3.65% | 3.17% |
| Average Diluted Shares Outstanding | 5.22% | 3.93% | 3.25% | 2.12% | 2.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |